<DOC>
	<DOCNO>NCT03006367</DOCNO>
	<brief_summary>This open-label , single ascend dose , pharmacokinetic , tolerability study NFC-1 Children Adolescents ( Ages 6-17 Years ) ADHD .</brief_summary>
	<brief_title>Pharmacokinetic Tolerability Study NFC-1 Subjects Aged 6-17 Years With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1 . Subject parent/legally authorize representative ( LAR ) able speak English fluently provide write informed consent , assent ( applicable ) study . 2 . Subject 6 17 year inclusive time consent/assent . 3 . Subject male , female nonchildbearing potential nonpregnant , nonlactating female childbearing potential agrees comply applicable contraceptive requirement 2 week prior administration IP throughout study . 4 . Subject meet Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criteria primary diagnosis ADHD base M.I.N.I . International Neuropsychiatric Interview . 5 . Subject consider `` healthy '' . Healthy status define absence evidence active chronic disease ADHD follow detailed medical surgical history , complete physical examination . 6 . Subject ability swallow capsule investigational product whole . 1 . Subject history hematological , hepatic , respiratory , cardiovascular , renal , neurological , psychiatric disease , gall bladder removal , current recurrent disease ADHD . 2 . Subject current relevant history physical psychiatric illness , medical disorder may require treatment . 3 . Subject current , control uncontrolled , comorbid psychiatric diagnosis significant symptom . 4 . Subject consider suicide risk opinion investigator , previously make suicide attempt , currently demonstrate active suicidal ideation . 5 . Subject use investigational product , enrol clinical study include vaccine , change eat habit , within 30 day prior first dose investigational product . 6 . Subject positive screen alcohol drug abuse , positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) , HIV antibody screen . 7 . Subject previously adolescent ( 1217 ) either screen failure , enrol participate study another NFC1 clinical study . 8 . Subject currently take medication might confound result safety assessment conduct study . 9 . Subject concurrent chronic acute illness , disability , condition might confound result safety assessment conduct study . 10 . Subject unwilling discontinue current ADHD medication participate study . 11 . Subject clinical laboratory abnormality indicate clinically significant hematologic , hepatobiliary , renal disease .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>